A Post Market Evaluation After Treatment of Nasolabial Folds

NCT ID: NCT02179736

Last Updated: 2022-08-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 114 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-07-31
• Study Completion Date: 2016-01-31

Brief Summary

This is an open, non-comparative study to evaluate effectiveness and safety of Restylane in correction of nasolabial folds up to 12 months after the initial treatment, and to evaluate the safety of repeat treatment of the nasolabial folds 12 months after the initial treatment.

Conditions

Nasolabial Folds

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Active treatment

Group Type: EXPERIMENTAL

Restylane

Intervention Type: DEVICE

Interventions

Restylane

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• 18 years or older
• Intent to undergo correction of both nasolabial folds
• WRSR 3-4
• Signed informed consent

Exclusion Criteria

• Markedly indurate defects such as significant mid-face volume loss or prominent commissures.
• Active skin disease, inflammation or related conditions, such as infection, psoriasis and herpes zoster near or in the area to be treated.
• Subjects with known hypersensitivity to any ingredient of the study product or anaesthesia used in the study.
• Concomitant anticoagulant therapy and therapy with inhibitors of platelet aggregation, (e.g. non-steriodal anti-inflammatory drugs, acetylsalicylic acid, Omega 3 and Vitamin E) within 2 weeks prior to treatment, or a history of bleeding disorders.
• Concomitant treatment with chemotherapy, immunosuppressive agents, immunomodulatory therapy (e.g. monoclonal antibodies), systemic or topical (facial) corticosteroids. (Inhaled corticoids are allowed).
• Cancerous or pre-cancerous lesions in the treatment area.
• Subjects who have performed aesthetic facial surgery.
• Tissue augmenting therapy with non-permanent filler or neurotoxin below the lower orbital rim in the last 12 months.
• Facial laser treatment or chemical peeling below the lower orbital rim during the last 6 months.
• Permanent implant or filler, including fat-injections, placed in the area to be treated.
• Women who are pregnant or breast feeding or who are planning to become pregnant during the study period.
• Participation in any other clinical study within 30 days prior to inclusion.
• Any medical condition that in the opinion of the investigator would make the subject unsuitable for inclusion (e.g. a chronic, relapsing or hereditary disease that may affect the general condition or may require frequent medical treatment, psychiatric disorders or subjects not likely to comply to study procedures or to avoid other facial cosmetic treatments below the lower orbital rim).
• Subjects who are study site staff for this study, or close relatives (defined as parents, siblings, children or spouse) of the study site staff, as well as subjects who are employed by the sponsor company, or close relatives of employees at the sponsor company.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Galderma R&D

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Plastic Surgery InstituteNo

No. 33 Badachu Road, Shijingshan District, Beijing Municipality, China

Countries

China

Other Identifiers

05DF1312

Identifier Type: -

Identifier Source: org_study_id